Gene and cell therapies, which can be transformational for patients, are attractive investment targets for other reasons as well. “People are looking at what is probably a once in a lifetime opportunity in terms of new modalities for therapeutics via gene therapy, cell therapy, and the potential to completely change medicine,” said Mike Dombeck, chief operating officer at Arcellx, Inc., a clinical stage cell therapy company. It helps, too, that the FDA has created a welcoming regulatory environment for cell and gene therapies, and that early stage companies can turn into late stage companies rapidly.
Regarding the flow of investment funds into gene and cell therapies, Dombeck credited “good old fashioned NPV analyses,” or net...
